Everstar Asset Management LLC Makes New $792,000 Investment in Zoetis Inc. $ZTS

Everstar Asset Management LLC bought a new stake in Zoetis Inc. (NYSE:ZTS) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 11,025 shares of the company’s stock, valued at approximately $792,000.

Other large investors have also modified their holdings of the company. Prosperity Bancshares Inc purchased a new position in shares of Zoetis during the 4th quarter worth $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zoetis during the 1st quarter worth about $28,000. Root Financial Partners LLC raised its holdings in Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after buying an additional 103 shares during the period. Elyxium Wealth LLC purchased a new stake in Zoetis in the 4th quarter valued at about $32,000. Finally, Wellington Grp LLC lifted its position in Zoetis by 6,675.0% in the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after buying an additional 267 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ZTS. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. JPMorgan Chase & Co. reduced their price target on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. Weiss Ratings lowered shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Zacks Research cut shares of Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. Finally, Barclays dropped their target price on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a report on Wednesday, July 1st. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Zoetis has an average rating of “Hold” and a consensus price target of $109.62.

Zoetis Price Performance

ZTS opened at $73.64 on Friday. The stock’s 50-day moving average price is $76.30 and its 200 day moving average price is $99.01. Zoetis Inc. has a 12-month low of $71.45 and a 12-month high of $160.48. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The firm has a market cap of $30.43 billion, a price-to-earnings ratio of 12.13, a PEG ratio of 1.31 and a beta of 0.74.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.Zoetis’s revenue was down .2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 6.19 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.9%. Zoetis’s dividend payout ratio (DPR) is presently 34.93%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.